Iulii 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACTUS Therapeutici et ProBio GenScript sunt in processu signandi contractum ad evolutionem et productionem plasmidis et virus vectoris ad primum pipeline ACTUS Therapeuticorum' Provectus CAR-T Platform (ACT suggestus), qui etiam mittendus est ad materias rudis producendas. pro ACTUS Therapeuticorum fistularum subsequentium. Contractus productionem plasmidum et virum vectorem operiet pro prima pipeline actuum therapeuticorum 'Provectus CAR-T Platform'.
Ob hanc conventionem, GenScript ProBio ad socium globalis statum elevatum est qui ACT suggestus pro ACT therapeuticis sustinere potest.
ACTUS suggestum est cellula proximae generationis et technologiae gene therapiae quae scuta cancri antigenis inserendo gena designantur ut illos antigenos in cellas immunes oppugnaant. Haec genera in cellas immunes per usum vectoris virus traduntur. GenScript ProBio summus qualitas virium evolutionis vectoris possidet ac unum-stium ministerium suggestum GMP productionis, quarum utraque necessaria est ad evolutionem cellae et therapiae gene.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing sanguinem cancer. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, CEO ACTUS Therapeuticorum, dixit, "Actus suggestum complevimus ut per opportuna societate cum ProBio GenScript societatem globalem emergere" confecimus. Acceleremus progressum curationum nisi refractoriae et intractabiles carcinomata solida ».
De GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Ad missionem "Innovationis per Collaborationem" GenScriptum ProBio committitur ut clientibus adiuvandis tempus minuat ad medicamentorum biologicorum progressionem ab indagatione ad mercaturam, signanter R&D demisso sumptuum et futurum salubrius aedificando.
